Numinus Wellness brings on five new executives to help support growth across Health, R&D and Bioscience divisions

Numinus Wellness Inc (CVE:NUMI) has announced a series of new hires at the leadership table. The psychedelics firm has brought on five new executives to support growth across its Health, R&D and Bioscience divisions. Numinus told shareholders that the new team will support its aim to expand its clinic network internationally, develop and market psychedelic-assisted psychotherapies and boost laboratory capabilities. READ: Numinus Wellness and Optimi Health submit evidence package to Health Canada for all-natural psilocybin extract Corporate finance executive Wajahat Ali is joining as director of merger and acquisitions, with Jason Lapensee, former director of operations at Dawson Dental Centres, to become the company’s new vice president of national clinic operations. Ian Noble is coming onboard to lead Numinus’ communication strategy as chief communication officer and Raseel Sehmi will head up business development and strategic partnerships as vice president. Finally, Pam Sethi, most recently the chief innovation officer at the Institute for Advancement in Mental Health, is joining as the company’s vice president of experience design and innovation. "At Numinus, our rapidly growing team of proven and experienced medical, business and clinical leaders are building the future of mental health care," said Payton Nyquvest, Numinus’ CEO in a statement. "Today's new hires are collaborative leaders who have the expertise and ambition to effectively scale our company while supporting our vision to help people to heal and be well." Vancouver-based Numinus is the first public company in Canada to receive a licence to produce and extract psilocybin from mushrooms. Contact Angela at angela@proactiveinvestors.com Follow her on Twitter @AHarmantas